CTOs on the Move

Segetis

www.segetis.com

 
Segetis, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.segetis.com
  • 680 Mendelssohn Ave N
    Minneapolis, MN USA 55427
  • Phone: 763.795.7200

Executives

Name Title Contact Details

Similar Companies

Afrivax

Afrivax is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Trellis Bioscience

Trellis Bioscience is a leader in identifying rare protective antibodies by screening human blood cells.

Clear Cycle

Clear Cycle is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Palvella Therapeutics

Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments.

Sesen Bio

We are passionate in our commitment to improving and renewing people`s lives. Sesen Bio is a late-stage company devWe are passionate in our commitment to save and improve the lives of patients. Sesen Bio is a late-stage company developing fusion protein medicines for the treatment of patients with cancer. In February 2021, the FDA accepted for filing the Company`s BLA for Vicineum™, a potential best-in-class treatment for non-muscle invasive bladder cancer.eloping fusion protein medicines for people with cancer. Our fusion protein approach tethers a tumor-targeting antibody fragment to a protein cytotoxic payload to form a single protein molecule designed to selectively and broadly kill cancer cells while sparing healthy cells and to activate the body`s innate immune response system. The most advanced program in our pipeline is Vicinium™, a novel investigational anti-cancer treatment that has the potential to treat multiple cancers driven by overexpression of EpCAM, such as non-muscle invasive bladder (NMIBC) and squamous cell carcinoma of the head and neck (SCCHN). We are currently advancing Vicinium in a Phase 3 registration trial for the treatment of people with NMIBC who have been previously treated with bacillus Calmette-Guérin (BCG), with positive three-month efficacy results established and 12-month study results expected in mid-2019. Due to Vicinium`s potential to promote an anti-tumor immune response, we believe it holds promise as a combination treatment with immuno-oncology drugs, such as checkpoint inhibitors.